What is Briacell Therapeutics Corp.'s earnings per share (EPS)?

Briacell Therapeutics Corp. (BCTX) reported diluted earnings per share of -$62.19 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Briacell Therapeutics Corp. (BCTX) Financials

BCTX

FY2025 annual

Revenue Not reported for FY2025

Net Income -$26.3M -449.1% YoY

EPS (Diluted) -$62.19 YoY not available

Operating Cash Flow -$28.2M -16.8% YoY

Market Cap $34.8M as of Oct 7, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.5x on $23.4M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Apr 30, 2026 Reported Jun 9, 2026 Currency USD FYE July

Newest figures come from the 10-Q for Q3 FY2026, filed Jun 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BCTX SEC filings page.

This page shows Briacell Therapeutics Corp. (BCTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BCTX FY2025 2026-10-04

Research-heavy operations consume cash, while the balance sheet has recently relied materially on financing rather than internal generation.

In FY2025, financing supplied $45.4M while operations used $28.2M, and equity was positive after two negative years; balance-sheet repair coincided with external funding rather than operating self-financing.

Reported research spending was $21.3M in FY2025 against $5.9M of selling, general and administrative costs, making scientific investment the dominant operating expense. The company therefore appears organized around development spending rather than a revenue-producing operating base, since revenue was not reported.

FY2024 paired a net loss of $4.8M with operating cash flow of -$24.1M; in FY2025, the net loss widened to $26.3M while operating cash flow was -$28.2M. That narrowing gap indicates earnings and cash consumption became more aligned, while reported liquidity equaled 7.6 months of the latest annual operating outflow.

Financial Health Signals

Financial health score not available

Briacell Therapeutics Corp. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Briacell Therapeutics Corp. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Briacell Therapeutics Corp. reported a net loss of $26.3M while operations used $28.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Briacell Therapeutics Corp. reported an operating loss of $27.2M against $37K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$7.6M

YoY-20.4%

QoQ-1.1%

Briacell Therapeutics Corp.'s EBITDA was -$7.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.4% from the same quarter a year earlier. Against the prior quarter it is down 1.1%.

Net Income

-$7.2M

YoY-16.9%

QoQ+0.8%

Briacell Therapeutics Corp. reported -$7.2M in net income in Q3 2026. This represents a decrease of 16.9% from the same quarter a year earlier. Against the prior quarter it is up 0.8%.

EPS (Diluted)

-$0.99

Briacell Therapeutics Corp. earned -$0.99 per diluted share (EPS) in Q3 2026.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt

$6.9M

YoY-44.8%

QoQ-77.0%

Briacell Therapeutics Corp. held $6.9M in cash as of Q3 2026; long-term debt is not reported for that period.

Shares Outstanding

Briacell Therapeutics Corp. had 9M shares outstanding in Q3 2026.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity

-30.6%

YoY+20.7pp

QoQ-6.7pp

Briacell Therapeutics Corp.'s ROE was -30.6% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is up 20.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.7 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending

$6.0M

YoY+24.0%

QoQ-1.4%

Briacell Therapeutics Corp. invested $6.0M in research and development in Q3 2026. This represents an increase of 24.0% from the same quarter a year earlier. Against the prior quarter it is down 1.4%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

BCTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BCTX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K
R&D Expenses	N/A	$21.3M-21.7%	$27.2M+77.2%	$15.3M+91.2%	$8.0M+296.9%	$2.0M
SG&A Expenses	N/A	$5.9M-3.5%	$6.2M-22.5%	$7.9M+9.2%	$7.3M+46.7%	$5.0M
Operating Income	N/A	-$27.2M	N/A	-$23.3M-52.2%	-$15.3M-119.2%	-$7.0M
EBITDA	N/A	-$27.1M	N/A	N/A	-$15.3M-119.4%	-$7.0M
Interest Expense	N/A	$37K	N/A	N/A	$979-98.8%	$79K
Income Tax	N/A	N/A	N/A	N/A	$0	$0
Net Income	N/A	-$26.3M-449.1%	-$4.8M+76.4%	-$20.3M+24.4%	-$26.8M-94.3%	-$13.8M
EPS (Basic)	N/A	-$62.19-42.4%	-$43.68-3260.0%	-$1.30+24.9%	-$1.73+43.5%	-$3.06
EPS (Diluted)	—	-$62.19	-$43.68	-$1.30+24.9%	-$1.73	N/A
Diluted Shares (Avg)	N/A	423,114	109,699	16M+0.8%	15M	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
R&D Expenses	$6.0M+24.0%	$6.1M+6.5%	$6.7M+82.3%	N/A	$4.8M-37.2%	$5.7M-31.2%	$3.7M-46.5%	N/A
SG&A Expenses	$1.7M+9.0%	$1.5M-0.5%	$1.6M+10.2%	N/A	$1.5M-3.4%	$1.5M-5.6%	$1.5M-9.6%	N/A
Operating Income	-$7.6M-20.4%	-$7.5M-5.0%	-$8.3M-61.5%	N/A	-$6.3M+31.4%	-$7.2M+27.1%	-$5.2M+39.4%	N/A
EBITDA	-$7.6M-20.4%	-$7.5M-5.1%	-$8.3M-61.8%	N/A	-$6.3M+31.7%	-$7.1M+27.3%	-$5.1M+39.6%	N/A
Interest Expense	$30K-19.9%	N/A	N/A	N/A	$37K	N/A	N/A	N/A
Net Income	-$7.2M-16.9%	-$7.2M-14.8%	-$8.2M-41.3%	N/A	-$6.1M-457.1%	-$6.3M+44.3%	-$5.8M-196.7%	N/A
EPS (Basic)	-$0.99+94.0%	-$2.58+88.9%	-$4.35+86.7%	-$55.49-37.6%	-$16.42-1119.9%	-$23.31-119.1%	-$32.67-8697.4%	-$40.32-26780.0%
EPS (Diluted)	-$0.99	-$2.58	-$4.35	-$55.49	-$16.42	-$23.31	-$32.67	-$40.32
Diluted Shares (Avg)	7M	3M	2M	N/A	373,067	269,957	177,606	N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

BCTX Balance Sheet

BCTX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K
Total Assets	$21.6M+268.7%	$5.9M-78.4%	$27.2M-36.2%	$42.6M-26.6%	$58.0M
Current Assets	$19.9M+445.4%	$3.7M-86.4%	$26.9M-36.4%	$42.3M-26.7%	$57.8M
Cash & Equivalents	$10.5M+1117.3%	$862K-95.9%	$21.3M-48.2%	$41.0M-28.3%	$57.3M
Short-Term Investments	$7.4M	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	$19K-21.7%	$24K+91.7%	$13K
Long-Term Investments	$0	$0	$0	$0	$0
Total Liabilities	$4.3M-49.6%	$8.6M-72.3%	$30.9M-4.1%	$32.2M+6.2%	$30.4M
Current Liabilities	$4.0M-46.7%	$7.5M+314.2%	$1.8M+91.4%	$941K+69.0%	$557K
Non-Current Liabilities	$338K-69.2%	$1.1M-96.2%	$29.1M-6.9%	$31.3M+5.0%	$29.8M
Total Equity	$17.3M+745.6%	-$2.7M+28.9%	-$3.8M-136.6%	$10.3M-62.7%	$27.7M
Retained Earnings	-$111.8M-30.8%	-$85.4M-5.9%	-$80.7M-33.6%	-$60.3M-107.1%	-$29.1M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$27.1M+59.2%	$33.6M+258.8%	$13.1M+25.5%	$21.6M+268.7%	$17.0M+174.1%	$9.4M-23.4%	$10.4M-44.1%	$5.9M-78.4%
Current Assets	$25.4M+71.7%	$32.2M+349.3%	$11.3M+38.1%	$19.9M+445.4%	$14.8M+167.4%	$7.2M-39.0%	$8.2M-55.4%	$3.7M-86.4%
Cash & Equivalents	$6.9M-44.8%	$29.9M+496.4%	$2.7M-53.1%	$10.5M+1117.3%	$12.5M+1231.7%	$5.0M-19.7%	$5.8M-57.6%	$862K-95.9%
Short-Term Investments	$15.9M	$0	$7.5M	$7.4M	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$3.7M-27.6%	$3.4M-44.9%	$3.7M-44.4%	$4.3M-49.6%	$5.1M-59.3%	$6.1M-70.1%	$6.7M-58.4%	$8.6M-72.3%
Current Liabilities	$3.6M-17.1%	$3.2M-39.1%	$3.3M-33.5%	$4.0M-46.7%	$4.3M-35.9%	$5.2M+33.3%	$5.0M+376.7%	$7.5M+314.2%
Non-Current Liabilities	$72K-90.2%	$195K-78.5%	$407K-76.2%	$338K-69.2%	$730K-87.1%	$906K-94.6%	$1.7M-88.6%	$1.1M-96.2%
Total Equity	$23.4M+96.0%	$30.2M+836.3%	$9.4M+151.8%	$17.3M+745.6%	$11.9M+291.6%	$3.2M+138.8%	$3.7M+47.6%	-$2.7M+28.9%
Retained Earnings	-$134.3M-29.6%	-$127.2M-30.4%	-$120.0M-31.5%	-$111.8M-30.8%	-$103.7M-23.1%	-$97.5M-13.5%	-$91.2M-22.2%	-$85.4M-5.9%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

BCTX Cash Flow Statement

BCTX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K
Operating Cash Flow	-$30.8M	-$28.2M-16.8%	-$24.1M-1.6%	-$23.7M-90.2%	-$12.5M-61.1%	-$7.8M
Depreciation & Amortization	N/A	$107K+27.1%	$84K	N/A	$15K+0.1%	$15K
Stock-Based Compensation	N/A	$777K-56.9%	$1.8M-17.8%	$2.2M-28.6%	$3.1M+56.2%	$2.0M
Capital Expenditures	N/A	N/A	$457K	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	-$24.6M	N/A	N/A	N/A
Investing Cash Flow	-$16.2M	-$7.6M-1021.4%	-$682K	N/A	N/A	N/A
Financing Cash Flow	N/A	$45.4M+928.5%	$4.4M+11.7%	$4.0M+205.7%	-$3.7M-105.8%	$65.0M
Share Buybacks	N/A	N/A	N/A	$47K-99.5%	$10.2M	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	-$7.0M+2.0%	-$8.0M-34.6%	-$7.7M-10.8%	-$8.1M-101.5%	-$7.2M-40.9%	-$5.9M+20.0%	-$7.0M+8.5%	-$4.0M+63.0%
Depreciation & Amortization	$29K+27.8%	$23K0.0%	$23K0.0%	$23K	$23K+498.5%	$23K+498.0%	$23K+498.2%	N/A
Stock-Based Compensation	N/A	$286K+0.3%	$295K+10.4%	N/A	$225K-42.7%	$285K-43.0%	$267K-50.0%	N/A
Investing Cash Flow	-$16.0M-15141.0%	$7.3M+9810.0%	-$75K0.0%	-$7.4M-1518.0%	-$105K	-$75K	-$75K	-$457K
Financing Cash Flow	$0-100.0%	N/A	N/A	$13.6M	$14.7M	$5.2M	$12.0M	N/A

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

BCTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BCTX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K
Return on Equity	-151.8%	N/A	N/A	-259.8%-209.9pp	-49.9%
Return on Assets	-121.5%-39.9pp	-81.6%-6.9pp	-74.7%-11.7pp	-63.0%-39.2pp	-23.8%
Current Ratio	5.01+4.5x	0.49-14.5x	14.96-30.0x	45.00-58.8x	103.81
Debt-to-Equity	0.25	N/A	N/A	3.12+2.0x	1.10

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Return on Equity	-30.6%+20.7pp	-23.9%+171.1pp	-87.7%+68.6pp	N/A	-51.3%	-195.0%	-156.3%-394.8pp	N/A
Return on Assets	-26.5%+9.6pp	-21.5%+45.7pp	-62.7%-7.0pp	N/A	-36.0%-63.7pp	-67.2%+25.1pp	-55.7%-87.9pp	N/A
Current Ratio	7.07+3.7x	10.10+8.7x	3.42+1.8x	5.01+4.5x	3.41+2.6x	1.37-1.6x	1.65-15.9x	0.49-14.5x
Debt-to-Equity	0.16-0.3x	0.11-1.8x	0.40-1.4x	0.25	0.42	1.90	1.80-4.6x	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Briacell Therapeutics Corp. BCTX	FY2025	N/A	-$26.3M	N/A	$34.8M	—
NextCure, Inc. NXTC	FY2025	N/A	-$55.8M	N/A	$26.0M	—
Imunon, Inc. IMNN	FY2025	N/A	$14.5M	N/A	$6.3M	—
Adaptimmune Therapeutics plc American ADAP	FY2024	$178.0M	-$70.8M	-39.8%	$14.6M	46/100
Portage Biotech Inc. PRTG	FY2018	N/A	$123.7M	N/A	$15.5M	—
Cyclacel Pharmaceuticals, Inc CYCC	FY2025	$747K	$3.0M	N/A	$15.2M	—

Where Briacell Therapeutics Corp. Ranks

Frequently Asked Questions

Is Briacell Therapeutics Corp. profitable?

No, Briacell Therapeutics Corp. (BCTX) reported a net income of -$26.3M in fiscal year 2025.

What is Briacell Therapeutics Corp.'s EBITDA?

Briacell Therapeutics Corp. (BCTX) had EBITDA of -$27.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Briacell Therapeutics Corp.'s return on equity (ROE)?

Briacell Therapeutics Corp. (BCTX) has a return on equity of -151.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Briacell Therapeutics Corp.'s operating cash flow?

Briacell Therapeutics Corp. (BCTX) recorded an outflow of $28.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Briacell Therapeutics Corp.'s total assets?

Briacell Therapeutics Corp. (BCTX) had $21.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Briacell Therapeutics Corp. spend on research and development?

Briacell Therapeutics Corp. (BCTX) invested $21.3M in research and development during fiscal year 2025.

How many shares does Briacell Therapeutics Corp. have outstanding?

Briacell Therapeutics Corp. (BCTX) had 2M shares outstanding as of fiscal year 2025.

What is Briacell Therapeutics Corp.'s current ratio?

Briacell Therapeutics Corp. (BCTX) had a current ratio of 5.01 as of fiscal year 2025, which is generally considered healthy.

What is Briacell Therapeutics Corp.'s debt-to-equity ratio?

Briacell Therapeutics Corp. (BCTX) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Briacell Therapeutics Corp.'s return on assets (ROA)?

Briacell Therapeutics Corp. (BCTX) had a return on assets of -121.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Briacell Therapeutics Corp.'s P/E ratio?

Briacell Therapeutics Corp. (BCTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $34.8M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Briacell Therapeutics Corp.'s price-to-sales ratio?

Briacell Therapeutics Corp. (BCTX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $34.8M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Briacell Therapeutics Corp.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Briacell Therapeutics Corp. (BCTX) held $17.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $28.2M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Briacell Therapeutics Corp.'s Piotroski F-Score?

Briacell Therapeutics Corp. (BCTX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Briacell Therapeutics Corp.'s earnings high quality?

Briacell Therapeutics Corp. (BCTX) reported a net loss of $26.3M while operations used $28.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Briacell Therapeutics Corp. cover its interest payments?

Briacell Therapeutics Corp. (BCTX) reported an operating loss of $27.2M against $37K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.